FDA approves Medicines Co's ORBACTIV for use in acute bacterial skin and skin structure infections

Medicines Co:Says that the U.S. Food and Drug Administration has approved ORBACTIV (oritavancin) for injection for the treatment of adults with acute bacterial skin and skin structure infections caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus...

Thursday, 7 Aug 2014

Endo International PLC raises FY 2014 guidance

Endo International PLC:Raised FY 2014 revenues to a range from $2.78 -$2.86 bln, an increase versus prior range of $2.72 -$2.80 bln.Raised FY 2014 adjusted diluted EPS to a range from $4.00 to $4.20, an increase versus prior range of $3.80 to $4.00.Expects FY 2014 diluted (GAAP) loss per share to be...

Thursday, 7 Aug 2014

DepoMed Inc raises FY 2014 revenue guidance and reaffirms FY 2014 EPS guidance

DepoMed Inc:Raises FY 2014 total revenue guidance of about $215-$230 mln, which includes non-cash revenues related to the PDL transaction and $15 mln in milestones already received in 2014 from Mallinckrodt.Raises FY 2014 GAAP EPS of about $0.36-$0.51, which includes the non-cash PDL revenues and...

Thursday, 7 Aug 2014

Theravance Inc appoints Michael W. Aguiar as president and chief executive officer

Theravance Inc:Appoints Michael W. Aguiar as President and Chief Executive Officer of the company effective Aug. 15, 2014 and as a member of the Board of Directors effective immediately.

Thursday, 7 Aug 2014


  • Sectors
  • Asia
  • U.S.
  • Europe

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.